Summary Hormonal regulation of plasminogen activator expression in 7,12-dimethylbenz [a]anthracene (DMBA) -induced rat mammary carcinomas was studied both in vivo and in vitro and was compared to that in DMBA-mammary dysplasia induced in neonatally androgenised rats. The plasminogen activator activity in DMBA-mammary carcinomas, but not in DMBA-mammary dysplasia, was regulated by oestrogen. This suggests that expression of this enzyme is hormonally regulated in carcinoma cells. Furthermore, in two of six DMBA-mammary carcinoma groups classified in terms of hormonal treatment, plasminogen activator activity was not under the control of oestrogen. Thus, the present results suggest that at the time of carcinogenesis, the hormonal milieu determines the hormone sensitivities of the malignant cells.
The 7,12-dimethylbenz [a] anthracene (DMBA) -induced rat mammary tumour model is valuable for studying the hormonal dependence of breast cancer in humans. In this model system, several studies have provided evidence that the oestrogen receptor is present in breast cancer cells (King et al., 1965; Mobbs, 1966) . After Yoshida et al. (1978) revealed that rat mammary dysplasia, which is morphologically similar to its human counterpart, is induced in neonatally androgenised rats (NA rats) by DMBA, this experimental model became useful for investigations of neoplastic transformation. We recently showed that in DMBA-induced rat mammary carcinomas and in the human breast cancer cell line, MCF-7, the production of plasminogen activator is regulated by oestrogen via an oestrogen receptor system, and pointed out that this enzyme can be a useful marker of oestrogen action in breast cancer cells (Yamashita et al., 1984; Yamashita et al., 1986) . Moreover, we have confirmed that in contrast to its effect on DMBA-carcinomas oestrogen has no effect on plasminogen activator activity in the rat uterus (Inada et al., 1991) . We speculate, therefore, that oestrogen regulates the cancer cell-specific gene expression of this enzyme. In the present study, we studied this hypothesis by comparing the effect of oestrogen on plasminogen activator production in DMBA-induced rat mammary carcinomas to that in mammary dysplasia induced in NA rats. We demonstrate that this enzyme is produced specifically in DMBA-induced carcinomas and that this enzyme is not necessarily regulated by oestrogen in some DMBA-induced carcinoma cells. We conclude that during carcinogenesis the hormonal milieu determines how plasminogen activator expression may be regulated in transformed cells.
Materials and methods

Chemicals
The synthetic substrate S-2251 (H-D-Val-Leu-Lys-pNA), human plasminogen, human plasmin and streptokinase were purchased from Kabi Diagnostica, Stockholm. 17 beta-oestradiol, progesterone, testosterone propionate, human melanoma t-PA, human urokinase, RNase and Triton X-100 were obtained from Sigma Chemical Co., St Louis, MO Assay for plasminogen activator Frozen tissue from each DMBA-tumour was homogenised and extracted with 50 mM Tris-HCI buffer (pH 7.4) containing 0.25% Triton X-100, as described previously (Yamashita et al., 1984; Yamashita et al., 1986) . Plasminogen activator activity was determined according to the method of Thorsen (1982) except that 0.76 mM S-2251 was employed as a substrate. One unit of the enzyme was defined as the amount of enzyme required to increase the optical density by 0.08 absorbance units in 2 h at 37°C. This unit corresponds to the International Unit (IU) employed to express streptokinase activity. Specific activity is expressed as units mg-' protein.
Protein concentrations were determined by the method of Bradford, using bovine serum albumin as the standard (Bradford, 1976) . The amount of plasmin inhibitor in the DMBAtumour extracts was determined by the method of Shimada et al. (1981) except that the reaction mixture contained bovine serum albumin (0.5 mg ml-'). No activity was detected in the tumour extracts, confirming that under the present assay conditions all hydrolytic activity in the tumour extracts was due to plasminogen activator.
Assay for oestrogen receptor
In each DMBA-induced rat mammary tumour in each group examined in the present study, oestrogen receptors were quantitated by the enzyme immunoassay method (Greene & Jensen, 1982) . Oestrogen receptors were deemed to be present at > 10 fmol receptor mg-' protein.
In vivo experiments The DMBA-tumour-bearing rats in Groups I-a and II-a were used for in vivo experiments. Four weeks after the tumours were first detected, the tumour-bearing rats were oophorectomised. One weekly after OVX, each rat was given a single subcutaneous dose of oestradiol (10 ytg in 10% ethanol solution/lOO g body weight). DMBA-induced tumours were removed under ether anesthesia at 4 h intervals up to 20 h after oestradiol administration. The plasminogen activator activity in each DMBA-induced tumour was assayed as described above.
In vitro experiments Primary cultures of DMBA-mammary tumour cells were initiated and maintained as described previously (Yamashita et al., 1984 
Results
Effects of sex steroids on DMBA-induced mammary tumours Three types of palpable mass were found in the mammary glands: mammary carcinomas, grossly visible cysts, and mammary dysplasia (regarded to be a benign lesion). The cystic nodules were soft and filled with a milky fluid, and were identified microscopically as epithelial cysts. Mammary dysplasia was characterised by heterogenous microscopic features including adenosis, fibrosis, duct papillomatosis and fibroadenoma-like lesions. It was difficult to distinguish by palpation mammary carcinomas from nodules. The most common type of mammary dysplasia is adenosis. Therefore, we used this histological type of dysplasia in both in vivo and in vitro experiments.
The effects of hormonal manipulation on DMBA-induced mammary tumours in rats are summarised in Table I . When 20 mg of DMBA was fed to the NI rats (Group I-a), 100% of the animals developed mammary carcinomas within 50-120 days, and oophorectomy performed simultaneously with DMBA administration prevented completely tumour induction (Group I-b).
Mammary tumours with the microscopic characteristics of dysplasia were induced in 88.9% of the NA rats (Group II-a) and the development of palpable carcinomas in this group was completely suppressed. In NA rats with OVX + P (Groups II-d and TI-f) and with OVX + E + P (Group II-e), the number of rats with palpable carcinomas increased significantly (P<0.001), as compared to NA rats (Groups IT-a), NA rats with OVX (Group 11-b) , or NA rats with OVX + E (Group TI-c). Furthermore, the incidence of DMBA-induced mamary carcinoma was higher in NA rats with P (Groups II-g and IT-h) than in NA rats with OVX + P (Groups II-d and II-f) or with OVX + E + P (Group II-e) (P<0.001).
Plasminogen activator activity in DMBA-induced rat mammary tumours Table II shows the plasminogen activator activity in DMBAinduced rat mammary tumours in each group. The enzyme activity was significantly higher in DMBA-induced carcinomas than in dysplasia. Lower activity was found in the II-d and IT-f carcinoma groups than in the other carcinoma groups.
In vivo effects of oophorectomy and oestrogen administration on plasminogen activator activity of DMBA-induced rat mammary carcinomas and dysplasia As shown in Figure 2 , the plasminogen activator activity of DMBA-induced rat mammary carcinomas was under the control of oestradiol in vivo. The plasminogen activator activity was 577 units mg-' protein. Within a week after oophorectomy, the activity decreased to less than 7% of baseline (37 units mg-' protein). After administering oestradiol to the oophorectomised tumour-bearing rats, the plasminogen activator activity of the tumours increased to reach a maximum of 376 units mg-' protein after 12 h. This was followed by a gradual decrease to 214 units mg-' protein at 20h.
DMBA-induced dysplasia displayed significantly lower plasminogen activator activity (68 units mg-' protein) than did DMBA-induced carcinomas. Furthermore, in sharp contrast to the carcinomas, the enzyme activity in dysplasia did change appreciably after oophorectomy or oestradiol administration.
In vitro effects of oestrogen on plasminogen activator activity in DMBA-induced rat mammary carcinomas and dysplasia We examined the effects of oestrogen on plasminogen activator activity in primary cultures of DMBA-induced rat mammary tumour cells in each group. As shown in Figure 3 , enzyme activity in the culture medium of group I-a carcinoma cells increased markedly in the presence of 10-8 M oestradiol, a concentration equivalent to the physiological level.
Furthermore, DMBA-induced rat mammary carcinoma cells in Groups II-e, II-g and II-h showed a similar oestrogen dependency of enzyme production. Since DMBA-induced rat mammary dysplasia (Groups II-a, II-g and II-h) showed no apparent increase in plasminogen activator activity on oestradiol administration, the hormonal regulation of this enzyme was considered to be specific to carcinoma cells. However, an exceptional result was obtained in an in vitro experiment with DMBA-induced rat mammary carcinoma cells from Groups II-d and II-f. These cells displayed no appreciable change in plasminogen activator activity, regardless of the presence or absence of oestradiol.
Oestrogen receptor in DMBA-tumours Table III shows the oestrogen receptor content of DMBAinduced rat mammary tumours in each group. The results confirm that each tumour examined in the present study was oestrogen receptor-positive and there were no significant difference in the oestrogen receptor content among the tumours in each group.
Discussion
There have been only a few reports of the relationship between progesterone and DMBA-mammary carcinogenesis (McCormick & Moon, 1965; Jabara et al., 1973; Nagasawa et al., 1986) . Since complicated interactions are observed at the cellular level among several hormones, such as oestrogen, progesterone and prolactin (Nagasawa & Morii, 1981) , it is difficult to specify the hormonal environment in the present 
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aPA activity; plasminogen activator activity (units mg-' protein). bNumbers in parentheses are the numbers of tumours examined. CDiffers from carcinoma groups; P < 0.001; dDiffers from the other carcinoma groups; P < 0.001. Time after oestradiol injection (hr) Figure 2 In vivo effects of oophorectomy and subsequent oestradiol administration on plasminogen activator activity in DMBA-tumours (0, mammary carcinomas in Group I-a; 0, mammary dysplasia in Group IT-a). One week after oophorectomy, each DMBA-tumour bearing rat was given by subcutaneous injection a single dose of oestradiol (10 1tg/100 g body weight). Tumours were removed at 4 h intervals up to 20 h and assayed for plasminogen activator activity as described under Materials and methods. Solid bars indicate the standard deviation of plasminogen activator activity and n denotes the number of animals tested. During the first week following oophorectomy, 28 mammary carcinoma tumours remained static and 14 of these regressed slightly, while all 42 mammary dysplasia tumours remained static.
experimental rats. According to earlier reports, however, the levels of serum prolactin and oestrogen in NA rats seem to be within normal range and similar to that in NI rats. The serum progesterone level is, however, much lower in NA rats, all of the corpora lutea being absent in the ovaries, than in NI rats (Yoshida et al., 1980; Cristakos et al., 1976) . The results obtained in the present investigation show that supplementation with progesterone in NA rats increases significantly the incidence of DMBA-induced rat mammary carcinoma. This effect is enhanced further by the co-administration of oestrogen (Table I) . Yoshida et al. (1978 Yoshida et al. ( , 1980 found, in a detailed study using NA (Howett et al., 1978; Unkeless et al., 1975; Duffy & O'Grady, 1984; Soumendra & Rajeswari, 1987; Butler et al., 1986 Time (hr) Figure 3 In vitro effects of oestrogen on plasminogen activator production. Cultures of DMBA-induced mammary carcinoma cells (Groups I-a, II-d, II-e, TI-f, 1I-g and 11-h) and mammary dysplasia cells (Groups II-a, 11-g and IT-h) were plated in 25-cm2 T-flasks and then incubated for 3 days in a serum-free medium prior to the experiments. After adding 10-8 M oestradiol (0) or the vehicle (0), aliquots of the culture medium were withdrawn at the indicated times and assayed for plasminogen activator activity as described under Materials and methods. Each point represents the mean value of four individual experiments. cinomas examined in the present study was confirmed to be oestrogen receptor-positive, with similar contents, the receptors of the mammary carcinoma cells in Groups II-d and 1I-f are considered to be non-functional. One explanation would be that an intact ovary is required to see oestrogen effects in culture and oestrogen preconditioning in vivo is required to get in vitro effects. Thus, these findings support the possibility that during carcinogenesis a hormonal difference contributes to the difference seen in the biologic characteristics of mammary carcinomas, such as the oestrogen dependency of plasminogen activator expression. To our knowledge, there has been no report to date of any significant relationship between hormonal control of plasminogen activator in DMBA-induced rat mammary tumours and the hormonal milieu during neoplastic transformation. DMBA-mammary tumours are prolactin dependent. High plasma levels of this hormone favor the development and subsequent growth of a mammary tumour, even in oophorectomised rats. A similar phenomenon observed upon the administration of oestrogen may be due to its stimulating prolactin secretion by the pituitary. This view was also supported by the finding that oestrogen has little effect on the growth of DMBA-mammary tumours in hypophysectomised rats. However, data which support the direct involvement of oestrogen are also available, in that in rats bearing DMBAmammary tumour and in which the hypothalamus had been destroyed, oophorectomy results in a rapid regression of tumours even while a high plasma levels of prolactin is maintained. It is difficult to specify whether in the present study the in vivo oestrogen dependency of DMBA-carcinoma is direct or indirect. However, the results of the in vitro studies of DMBA-induced carcinoma cells in primary culture (I-a, II-e, II-g and II-h) suggest strongly that oestrogen exerts its function directly. Taken together, our present data indicate that the hormonal milieu dictates the DMBA-induced tumour's hormone sensitivity and that in some of the resulting tumours, oestrogen exerts its effect directly by a route distinct from the prolactin pathway.
